FY2023 EPS Estimates for Lonza Group AG Cut by Analyst (OTCMKTS:LZAGY)

Lonza Group AG (OTCMKTS:LZAGY – Get Rating) – Analysts at KeyCorp cut their FY2023 EPS estimates for Lonza Group in a note issued to investors on Monday, May 22nd. KeyCorp analyst P. Knight now anticipates that the company will post earnings per share of $1.68 for the year, down from their previous forecast of $1.76. The consensus estimate for Lonza Group’s current full-year earnings is $1.72 per share. KeyCorp also issued estimates for Lonza Group’s FY2024 earnings at $2.14 EPS.

A number of other research analysts also recently commented on LZAGY. Stifel Nicolaus started coverage on shares of Lonza Group in a research report on Wednesday, May 17th. They set a “hold” rating on the stock. William Blair reaffirmed an “outperform” rating on shares of Lonza Group in a research report on Friday, February 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Lonza Group currently has an average rating of “Moderate Buy” and a consensus price target of $680.50.

Lonza Group Price Performance

Shares of LZAGY opened at $62.57 on Wednesday. The company’s 50 day moving average price is $62.39 and its 200 day moving average price is $57.07. Lonza Group has a 52 week low of $43.85 and a 52 week high of $65.96. The company has a quick ratio of 1.27, a current ratio of 1.86 and a debt-to-equity ratio of 0.15.

Lonza Group Increases Dividend

The company also recently disclosed a dividend, which will be paid on Friday, May 26th. Stockholders of record on Wednesday, May 10th will be paid a $0.108 dividend. This represents a dividend yield of 0.17%. This is a boost from Lonza Group’s previous dividend of $0.09. The ex-dividend date of this dividend is Tuesday, May 9th.

Lonza Group Company Profile

(Get Rating)

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle.